# TransMedics Group, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/TransMedics Group, Inc.).

## Overview

TransMedics Group, Inc. is a U.S.-based medical technology company focused on organ transplant therapy for end-stage organ failure. Its core platform includes the Organ Care System (OCS) for heart, lung, and liver transplantation, along with the National OCS Program (NOP), which combines organ procurement, perfusion management, and transplant logistics services.

## Products & services

• OCS Heart portable organ preservation system
• OCS Lung portable organ preservation system
• OCS Liver portable organ preservation system
• OCS disposable sets for transplant procedures
• National OCS Program (NOP) services
• Organ procurement, perfusion management, and logistics

- **OCS consoles and organ-specific systems** (55%) — Portable warm-perfusion systems used to preserve and assess donor hearts, lungs, and livers outside the body.
- **Disposable sets** (35%) — Single-use organ-specific sets consumed in each transplant procedure on the OCS platform.
- **NOP transplant services** (10%) — Outsourced organ procurement, perfusion management, and transplant logistics services in the U.S.

- OCS Heart portable organ preservation system
- OCS Lung portable organ preservation system
- OCS Liver portable organ preservation system
- OCS disposable sets for transplant procedures
- National OCS Program (NOP) services
- Organ procurement, perfusion management, and logistics

## Customers

Customers are transplant programs, hospitals, and academic medical centers that perform organ transplantation and need preservation technology plus procedural support. In the U.S., many customers also participate in the NOP, which bundles logistics and perfusion management around the OCS platform. The business is concentrated in a relatively small number of transplant centers and other institutional buyers that value clinical evidence, reimbursement support, and workflow integration.

- **U.S. transplant programs** (primary) — Buy OCS disposable sets and NOP services to support heart, lung, and liver transplant procedures.
- **Academic medical centers** (primary) — Use the OCS platform in complex transplant cases and clinical protocols, often influencing broader adoption.
- **International transplant centers** (secondary) — Purchase OCS products and related support for approved uses outside the United States.
- **Clinical trial and registry participants** (secondary) — Use the platform in studies that generate clinical evidence and support regulatory and commercial adoption.

- Transplant hospitals buying OCS systems and disposable sets
- Academic medical centers using the platform in clinical practice
- U.S. transplant programs purchasing NOP services
- Clinical trial sites generating evidence and early adoption
- Institutional buyers seeking reimbursement and workflow support

## Geography

The company is headquartered in Andover, Massachusetts and sells primarily in the United States, where the NOP is also deployed. International revenue is smaller but important for validating the platform across select non-U.S. transplant markets. Geography matters because transplant adoption, reimbursement, regulatory approvals, and logistics capabilities differ significantly by country.

- **United States** (97.4%) — Estimated from 9M 2025 OCS transplant revenue disclosure
- **All other countries** (2.6%) — Estimated from 9M 2025 OCS transplant revenue disclosure

- Headquartered in Andover, Massachusetts, United States
- U.S. is the main commercial market and NOP operating base
- International sales are concentrated in select transplant markets
- Revenue is heavily weighted to the United States
- Cross-border adoption depends on regulatory approvals and logistics

## Strategy

TransMedics is focused on expanding adoption of the OCS platform across heart, lung, and liver transplantation while building the clinical evidence base that supports broader use. It is also scaling the NOP, extending manufacturing and sterilization capacity, and pursuing additional organ indications and select non-U.S. markets.

- **Increase OCS adoption in transplant centers** (short-term) — More procedures drive recurring disposable-set demand and deepen platform penetration.
- **Scale the National OCS Program** (short-term) — NOP integrates logistics and perfusion management, making the platform easier to deploy at scale.
- **Advance next-generation and additional-organ products** (medium-term) — New indications can extend the platform beyond the current heart, lung, and liver base.

- Expand commercial adoption of OCS Heart, Lung, and Liver
- Grow the NOP as an integrated transplant services platform
- Increase manufacturing and sterilization capacity
- Develop next-generation OCS and additional organ applications
- Broaden clinical evidence through trials, registries, and publications
- Seek approvals in select non-U.S. markets

## Risks

The business depends on a concentrated set of transplant customers, regulatory approvals, reimbursement support, and reliable supply and logistics execution. It also faces adoption risk from alternative organ preservation methods, cybersecurity exposure, and international operating complexity, all of which can affect procedure volumes and platform utilization.

- **Customer concentration** [high] — A small number of transplant centers and programs generate a significant share of revenue.
- **Alternative organ preservation methods** [high] — Cold storage and normothermic regional perfusion can limit OCS adoption.
- **Supply chain concentration** [high] — The company relies on single-source and sole-source suppliers for many components.
- **Cybersecurity** [high] — The platform and company systems handle sensitive clinical and operational data.
- **Foreign operations** [medium] — International sales are exposed to political, economic, and regulatory differences.

- Revenue is concentrated in a limited number of transplant customers
- Adoption can be affected by competing preservation methods
- NOP execution depends on logistics, transport, and capacity
- Single-source suppliers create component supply interruption risk
- Cybersecurity incidents could disrupt systems and expose data
- Foreign operations add regulatory, political, and currency risk

## Accounting

Revenue recognition is central because the company sells disposable sets, consoles, and bundled NOP services, and each may be a separate performance obligation. Reported results can also be affected by clinical-trial related customer payments, inventory valuation, and estimates tied to variable consideration, while quarterly comparisons may be volatile because transplant procedure timing drives revenue recognition.

- **Revenue recognition for bundled transplant offerings** — Allocation across performance obligations affects timing and mix of reported revenue.
- **Variable consideration and customer payments** — Can change recognized revenue and operating expenses.
- **Inventory valuation** — Estimates affect cost of revenue and gross margin.
- **Quarterly seasonality and procedure timing** — Creates comparability issues in interim revenue and margin trends.

- Revenue is recognized when control transfers to the customer
- Disposable sets and NOP services are separate performance obligations
- Clinical-trial and post-approval customer payments require judgment
- Inventory valuation depends on component and manufacturing cost estimates
- Quarterly revenue can vary with transplant procedure timing

---

*Last updated: 2026-04-29T05:04:13.383948+00:00*